Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2019-04-16 Proxy Solicitation & In…
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM DEF 14C
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14C Information Statement filed pursuant to Section 14(c) of the Securities Exchange Act of 1934. It is a definitive information statement notifying stockholders of a reverse stock split approved by written consent of majority stockholders, without a meeting or proxy solicitation. The document details the terms, purpose, effects, and procedures related to the reverse stock split, including tax consequences and administrative instructions. It is not a proxy solicitation, voting results announcement, or a financial report. The form DEF 14C is specifically used for information statements related to corporate actions that do not require a shareholder meeting or proxy. This matches the Proxy Solicitation & Information Statement (PSI) category, which includes materials sent to shareholders to provide information and request votes for meetings or corporate actions. Although no vote is solicited here, the document is an information statement pursuant to SEC rules, fitting the PSI classification rather than other categories like Capital/Financing Update or Regulatory Filings. The document length and detail confirm it is the statement itself, not just an announcement of a report.
2019-04-16 English
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the offering, the company, risk factors, use of proceeds, management discussion, and financial statements. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of report but specifically a registration statement for a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not just an announcement or a brief notice.
2019-04-08 English
FORM PRE 14C
Share Issue/Capital Change Classification · 100% confidence The document is a Schedule 14C Information Statement filed with the SEC by BioCardia, Inc. It details a corporate action approved by written consent of majority shareholders regarding a reverse stock split. The document includes explanations of the reverse stock split, its purpose, effects, and procedural details. It is not a proxy solicitation but an information statement pursuant to Section 14(c) of the Securities Exchange Act of 1934. The content focuses on capital structure changes, specifically a reverse stock split, which is a form of capital change. There are no financial statements or earnings data, so it is not an annual or interim report. It is not a voting results declaration, but an information statement about a capital restructuring. The appropriate classification for this type of filing, which announces a capital structure change (reverse stock split), is Share Issue/Capital Change (SHA). The document length and detail confirm it is the filing itself, not just an announcement of a report, so it is not RPA or RNS.
2019-04-05 English
FORM NT 10-K
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, BioCardia, Inc., was unable to file its Annual Report on Form 10-K for the year ended December 31, 2018, within the prescribed time period and is notifying the SEC of this delay. The document does not contain the actual 10-K report or financial data but is a regulatory notification about the late filing of the 10-K. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to the filing process and not the report itself.
2019-04-02 English
FORM 10-K
Annual Report FY 2018
2019-04-01 English
FORM 4
Director's Dealing
2019-02-15 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.